entertainment -WSS

entertainment

author：hotspot 2025-09-30 01:01:44 - browse：1

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

WSS

EPA limits use of carcinogenic gas for sterilizing medical devices

Change Healthcare outage fallout shows need for new oversight

HHS secretary Becerra pressed on Change HealthCare cyberattack

Boston's new lab space is opening empty

Why scientists need input from humanists on sensitive research

Idaho abortion case may prompt more restrictions in other states

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Walensky prepares to leave CDC — and Congress — behind

New England Journal of Medicine addresses racist history, slavery

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The SUPPORT Act is critical to fighting the opioid crisis

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Amid AI frenzy, a top HHS official's quest to create safeguards

In age of alternative facts, a scholarly course on calling out crap

Why depression after traumatic brain injury is distinct

Bright Health sells Medicare Advantage business to Molina

Biotech reporter’s notebook: A sunnier mood at JPM 2024

knowledge

New England Journal of Medicine addresses racist history, slavery

Heart disease and mental health: A look at cardiac psychology

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Idaho abortion case may prompt more restrictions in other states

Why depression after traumatic brain injury is distinct

focus

leisure time

knowledge

focus